Zacks Investment Research
14 Aug 2026, 22:41 UTC · 6w ago
Verdict
Headline leans bearish. We score VVOS +0.20 across three claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.20slightly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Vivos Therapeutics reported a quarterly loss of $0.31 per share, beating the Zacks Consensus Estimate of a $0.42 loss.
More positive than 66% of claims this week
Vivos Therapeutics reported quarterly revenues of $5.15 million, missing the Zacks Consensus Estimate by 5.15%.
Continue reading
5 related stories
More positive than 57% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 68% of claims this week
Vivos Therapeutics shares have declined approximately 85% since the beginning of the year.
More negative than 62% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The company reported an earnings surprise with a smaller loss than estimated, although revenue missed estimates and the stock has significantly underperformed the market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
−57.2%
Price is moving against the score
$0.1470 vs $0.3433 close before publication (Aug 14) · not market-adjusted
VVOS chart →
